Asset profile
Ivonescimab
Multispecific antibody
Approvedregulatory verdict
Evidence outlook
Approved: monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small cell lung... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Weak signal
Also approved:CN: monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC) (product first approved 2025)CN: ivonescimab combined with platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI) (product first approved 2024)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ivonescimab: this drug | Phase 3 | Multispecific antibody | PD-1 + VEGFA | ||
| JS207 | Phase 2 | Multispecific antibody | PD-1 + VEGFA | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 46 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(123 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (15)
October 2026 (3)
Phase 2ESCC, Advanced Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-10-30 · NCT06489197 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2026-10-31 · NCT06718543 · CT.gov ↗
What to watch
Early phase / not applicableMSS/pMMR Type Metastatic Colorectal Adenocarcinoma PatientsEnrolling by invitation
Est. primary completion 2026-10-31 · NCT06936488 · CT.gov ↗
What to watch
November 2026 (1)
Phase 2CRC, MSS, Metastatic CancerNot yet recruiting
Est. primary completion 2026-11-01 · NCT06593548 · CT.gov ↗
What to watch
December 2026 (11)
Phase 1/2Solid Tumor, AdultRecruiting
Est. primary completion 2026-12 · NCT05689853 · CT.gov ↗
What to watch
Phase 3Triple-Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2026-12 · NCT06767527 · CT.gov ↗
What to watch
Phase 2Stomach Cancer Stage IV, Esophagus Cancer, Stomach CancerRecruiting
Est. primary completion 2026-12-01 · NCT07070466 · CT.gov ↗
What to watch
Phase 2Relapsed or Metastatic Thymic Cancer, First-line TreatmentNot yet recruiting
Est. primary completion 2026-12-20 · NCT06750952 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT06646055 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07086326 · CT.gov ↗
What to watch
Phase 2Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05227664 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant TumorsActive not recruiting
Est. primary completion 2026-12-31 · NCT05229497 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06769295 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06769971 · CT.gov ↗
What to watch
Phase 2SCLCNot yet recruiting
Est. primary completion 2026-12-31 · NCT06820762 · CT.gov ↗
What to watch
2027 (59)
January 2027 (7)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01 · NCT07208773 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-01 · NCT06196697 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-01 · NCT06601335 · CT.gov ↗
What to watch
Phase 3Colorectal AdenocarcinomaRecruiting
Est. primary completion 2027-01-13 · NCT06951503 · CT.gov ↗
What to watch
Phase 1/2Esophageal Squamous Cell Carcinoma, Ivonescimab, NeoadjuvantRecruiting
Est. primary completion 2027-01-28 · NCT07385001 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-01-30 · NCT07070479 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsNot yet recruiting
Est. primary completion 2027-01-31 · NCT07650825 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1/2Colorectal Cancer With Hepatic MetastasesNot yet recruiting
Est. primary completion 2027-02-28 · NCT07357220 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Rectal Cancer, Radiation, AK112Recruiting
Est. primary completion 2027-03-31 · NCT07162714 · CT.gov ↗
What to watch
April 2027 (2)
May 2027 (7)
Phase 1/2Biliary Tract CancerRecruiting
Est. primary completion 2027-05 · NCT06938321 · CT.gov ↗
What to watch
Phase 2Squamous Cell Lung CancerNot yet recruiting
Est. primary completion 2027-05 · NCT07009925 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT06928389 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-05-10 · NCT07052253 · CT.gov ↗
What to watch
Phase 2Cutaneous AngiosarcomaRecruiting
Est. primary completion 2027-05-11 · NCT07655570 · CT.gov ↗
What to watch
Phase 3Pancreatic CancerRecruiting
Est. primary completion 2027-05-14 · NCT06953999 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT07590531 · CT.gov ↗
What to watch
June 2027 (5)
Phase 1Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2027-06 · NCT06990620 · CT.gov ↗
What to watch
Phase 2Colorectal Liver MetastasesRecruiting
Est. primary completion 2027-06 · NCT06848842 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell CarcinomaEnrolling by invitation
Est. primary completion 2027-06-01 · NCT07488572 · CT.gov ↗
What to watch
Phase 2Thymus CarcinomaRecruiting
Est. primary completion 2027-06-17 · NCT06980077 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT07188103 · CT.gov ↗
What to watch
July 2027 (5)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-01 · NCT07630077 · CT.gov ↗
What to watch
Phase 2LOCALLY ADVANCED CERVICAL CANCERSNot yet recruiting
Est. primary completion 2027-07-01 · NCT07244965 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-07-10 · NCT06791148 · CT.gov ↗
What to watch
Phase 2Neoadjuvant Therapy of Operable Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-07-15 · NCT06537011 · CT.gov ↗
What to watch
Phase 1Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma …Not yet recruiting
Est. primary completion 2027-07-21 · NCT07363408 · CT.gov ↗
What to watch
August 2027 (5)
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-08 · NCT07114315 · CT.gov ↗
What to watch
Phase 2Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-08-01 · NCT07094685 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2027-08-03 · NCT06529718 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-30 · NCT07669779 · CT.gov ↗
What to watch
Phase 2Colon CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT06790212 · CT.gov ↗
What to watch
September 2027 (5)
Phase 2Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Advanced Gastric AdenocarcinomaRecruiting
Est. primary completion 2027-09 · NCT06846346 · CT.gov ↗
What to watch
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2027-09-01 · NCT07591090 · CT.gov ↗
What to watch
Phase 2Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 …Recruiting
Est. primary completion 2027-09-08 · NCT07226544 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07339839 · CT.gov ↗
What to watch
Phase 2Metastatic Endocrine Refractory, Triple Negative Invasive Lobular CarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT07229417 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07204548 · CT.gov ↗
What to watch
Phase 2Platinum-sensitive Ovarian CancerRecruiting
Est. primary completion 2027-10 · NCT06686030 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, IvonescimabNot yet recruiting
Est. primary completion 2027-10-31 · NCT07021950 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT07241819 · CT.gov ↗
What to watch
Phase 2Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular Epithelioid Cell Tumor …Recruiting
Est. primary completion 2027-11-30 · NCT06683846 · CT.gov ↗
What to watch
December 2027 (16)
Phase 2TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07017673 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2027-12 · NCT07245446 · CT.gov ↗
What to watch
Phase 2Extensive Stage Lung Small Cell CancerRecruiting
Est. primary completion 2027-12 · NCT07057791 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT06684873 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerNot yet recruiting
Est. primary completion 2027-12-20 · NCT06760520 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07603791 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-30 · NCT07647016 · CT.gov ↗
What to watch
Phase 1Melanoma, Mucosal Melanoma, Metastatic MelanomaEnrolling by invitation
Est. primary completion 2027-12-31 · NCT06424626 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07472478 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07489703 · CT.gov ↗
What to watch
Phase 2Breast Cancer - FemaleNot yet recruiting
Est. primary completion 2027-12-31 · NCT07103447 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07742956 · CT.gov ↗
What to watch
Phase 2Gastric Cancer, RCTNot yet recruiting
Est. primary completion 2027-12-31 · NCT07374250 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma, Neoadjuvant TherapyNot yet recruiting
Est. primary completion 2027-12-31 · NCT07244978 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma (STS)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07650838 · CT.gov ↗
What to watch
2028 (35)
January 2028 (4)
Phase 2Pretreated Pleural MesotheliomaRecruiting
Est. primary completion 2028-01 · NCT06875076 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT07669051 · CT.gov ↗
What to watch
Phase 2Ivonescimab, Clear Cell Renal CarcinomaRecruiting
Est. primary completion 2028-01-19 · NCT06940518 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2028-01-31 · NCT06672575 · CT.gov ↗
What to watch
February 2028 (2)
March 2028 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-01 · NCT07405190 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant TumorsRecruiting
Est. primary completion 2028-03-30 · NCT06877650 · CT.gov ↗
What to watch
Phase 2Metastatic Breast Cancer ( HER2 Negative), ctDNARecruiting
Est. primary completion 2028-03-31 · NCT07394218 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-31 · NCT07412262 · CT.gov ↗
What to watch
April 2028 (4)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07535437 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07535463 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT06767514 · CT.gov ↗
What to watch
Phase 2Gastric (Cardia, Body) CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT06904300 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Adrenocortical Carcinoma, Pheochromocytoma, ParagangliomaNot yet recruiting
Est. primary completion 2028-05-01 · NCT07743138 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-12 · NCT07594522 · CT.gov ↗
What to watch
Phase 3Metastatic Colorectal Cancer (CRC)Recruiting
Est. primary completion 2028-05-31 · NCT07228832 · CT.gov ↗
What to watch
June 2028 (4)
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2028-06-06 · NCT07560124 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-18 · NCT07623356 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06868732 · CT.gov ↗
What to watch
Phase 2Gallbladder CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07767994 · CT.gov ↗
What to watch
July 2028 (5)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-07 · NCT07614646 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07 · NCT07158489 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07-01 · NCT06951646 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-07-01 · NCT06959550 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
August 2028 (2)
September 2028 (2)
November 2028 (1)
Phase 2Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Not yet recruiting
Est. primary completion 2028-11-30 · NCT07393555 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07381075 · CT.gov ↗
What to watch
Phase 2/3Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma …Not yet recruiting
Est. primary completion 2028-12-31 · NCT07765433 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT07010263 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT05899608 · CT.gov ↗
What to watch
2029 (8)
January 2029 (1)
Phase 2TNBC, Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2029-01 · NCT06977542 · CT.gov ↗
What to watch
February 2029 (2)
April 2029 (1)
Phase 2LeiomyosarcomaRecruiting
Est. primary completion 2029-04 · NCT07516925 · CT.gov ↗
What to watch
May 2029 (2)
June 2029 (1)
Phase 1/2Neoplasms, LungRecruiting
Est. primary completion 2029-06-22 · NCT07602855 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2029-08 · NCT07359456 · CT.gov ↗
What to watch
2030 (2)
May 2030 (1)
Phase 3Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)Recruiting
Est. primary completion 2030-05 · NCT07264075 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (2)
May 2031 (1)
Phase 2Nasopharyngeal Carcinoma (NPC)Not yet recruiting
Est. primary completion 2031-05 · NCT07565389 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2Phase II, Ivonescimab, Intraperitoneal, Paclitaxel, High Grade Metastatic, Appendiceal AdenocarcinomaNot yet recruiting
Est. primary completion 2031-11-28 · NCT07753824 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.